.png){kind=icon}
返回
Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?
.png){kind=icon}
PRE
AI
DOI：10.1038/s41569-026-01278-8.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
血浆脂蛋白(a) (Lp(a))浓度升高是多种心血管疾病的重要危险因素。然而，迄今为止，临床医生尚未直接针对升高的Lp(a)水平进行治疗，因为Lp(a)水平几乎完全由遗传因素决定，且相对抵抗标准的降脂疗法。随着强效Lp(a)降低疗法的出现，这一未满足的医疗需求可能很快得到解决。
Keyword:
Lipoproteins
Risk factors
Medicine/Public Health
general
Cardiology
Cardiac Imaging
Cardiac Surgery
期刊
IF:
44.2
论文数:
314
被引数:
2.2W
机构
引用论文
Lipoprotein(a)-lowering therapies: a promising future脂蛋白(a)降低疗法：一个充满希望的未来.png)
European Heart Journal
European Heart JournalIF35.6
PREAI
分享收藏Assini, J.M.; Boffa, M.B.; Koschinsky, M.L. The complex pro-atherosclerotic role of lipoprotein(a): A multiplicity of cellular targets. Curr. Opin. Lipidol. 2025, 36, 268–275. [Google Scholar] [CrossRef]Assini, J.M.; Boffa, M.B.; Koschinsky, M.L. 脂蛋白(a)复杂的促动脉粥样硬化作用：多种细胞靶点。Curr. Opin. Lipidol. 2025, 36, 268–275. [Google Scholar] [CrossRef]
IF0
PREAI
分享收藏Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 RepeatsCLINICAL CHEMISTRY
OAAI
CLINICAL CHEMISTRYIF6.3
OAAI分享收藏Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers Results From the OCEAN(a)-DOSE TrialOlpasiran、氧化磷脂和系统性炎症生物标志物结果：来自OCEAN(a)-DOSE试验JAMA CARDIOLOGY
JAMA CARDIOLOGYIF14.1
PREAI
分享收藏Between Scylla and Charybdis – Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus在斯库拉与卡律布狄斯之间——脂蛋白(a)在动脉粥样硬化性心血管疾病和2型糖尿病中的神秘作用
PREAI
分享收藏Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National BiobankLp(a) (脂蛋白 [a]) 浓度与动脉粥样硬化性心血管疾病: 来自大型国家生物库的新见解OAAI
OAAI分享收藏 没有更多内容
没有更多内容